FIELD: medicine, pharmacology.
SUBSTANCE: invention relates to method of thrombocyte aggregation inhibition. Method consists in that therapeutically efficient amount of valsartan metabolite, valeryl-4-hydroxyvalsartan, is introduced to patient who needs it. Invention also relates to pharmaceutical composition including valeryl-4-hydroxyvalsartan, and to its application for prevention, slowing-down development or treatment of disease and disorder mediated by thrombocyte aggregation.
EFFECT: reduction of thrombocyte ability to aggregate.
3 cl, 4 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMBINATIONS OF ANGIOTENSINE RECEPTOR ANTAGONIST AND NEP INHIBITOR | 2006 |
|
RU2459809C2 |
| PHARMACEUTICAL COMBINATIONS OF ANGIOTENSIN RECEPTOR ANTAGONIST AND NEP INHIBITOR | 2006 |
|
RU2503668C2 |
| DOUBLE-ACTION PHARMACEUTICAL COMPOSITIONS OF SUBMOLECULAR STRUCTURE OF ANGIOTENSIN RECEPTOR BLOCKER (ARB) AND NEUTRAL ENDOPEPTIDASE (NEP) INHIBITOR | 2008 |
|
RU2493844C2 |
| PHARMACEUTICAL COMPOSITION | 1997 |
|
RU2183128C2 |
| NEP INHIBITORS FOR TREATMENT OF DISEASES CHARACTERIZED BY ATRIAL ENLARGEMENT OR REMODELING | 2018 |
|
RU2809222C2 |
| NEP INHIBITORS FOR TREATING DISEASES CHARACTERIZED BY ATRIAL ENLARGEMENT OR REMODELING | 2013 |
|
RU2667643C2 |
| USE OF RKS INHIBITORS IN DIABETES RELATED COMPLICATIONS | 2007 |
|
RU2447892C2 |
| VALSARTAN SALTS, PHARMACEUTICAL COMPOSITION BASED ON THEREOF AND METHOD FOR PREPARING SALTS | 2001 |
|
RU2275363C2 |
| GALENIC COMPOSITIONS OF ORGANIC COMPOUNDS | 2017 |
|
RU2773029C2 |
| TREATMENT OF HYPERTENSION AND/OR PREVENTION AND TREATMENT OF HEART FAILURE IN MAMMAL, RECEIVING ANTICOAGULANT THERAPY | 2011 |
|
RU2564941C2 |
